Form 13-F position report

AVIDITY BIOSCIENCES INC

Reported by MORGAN STANLEY

RNA CUSIP 05370A108 Manager CIK 0000895421

Reported 134,045 shares, up 24,673 (22.6%) from the prior quarter.

Reported value -3.6%; share count 22.6% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q2 2022
Shares 134,045 Quarter-end amount reported
Reported value $1,949,000 Fair value at quarter end
Consecutive quarters held 8 Through Q2 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 1778000
2022-03-31 2021000
2022-06-30 1949000
2022-09-30 1315000
2022-12-31 22741465
2023-03-31 19225292
2023-06-30 12183418
2023-09-30 7385373
2023-12-31 13491224
2024-03-31 39231793
2024-06-30 51235459
2024-09-30 28074117
2024-12-31 35296629
2025-03-31 15518547
2025-06-30 12663004
2025-09-30 30129207
2025-12-31 78800809
2026-03-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

18 quarters
Quarterly reported position history for AVIDITY BIOSCIENCES INC held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2026 Reduced 0 -1,092,482 (-100.0%) 0 $0 2026-05-15
Q4 2025 Added 1,092,482 +400,970 (58.0%) < 0.01% $78,800,809 2026-02-13
Q3 2025 Added 691,512 +245,632 (55.1%) < 0.01% $30,129,207 2025-11-14
Q2 2025 Reduced 445,880 -79,816 (-15.2%) < 0.01% $12,663,004 2025-08-15
Q1 2025 Reduced 525,696 -688,080 (-56.7%) < 0.01% $15,518,547 2025-05-15
Q4 2024 Added 1,213,776 +602,539 (98.6%) < 0.01% $35,296,629 2025-02-14
Q3 2024 Reduced 611,237 -642,997 (-51.3%) < 0.01% $28,074,117 2024-11-14
Q2 2024 Reduced 1,254,234 -283,062 (-18.4%) < 0.01% $51,235,459 2024-08-14
Q1 2024 Added 1,537,296 +46,553 (3.1%) < 0.01% $39,231,793 2024-05-15
Q4 2023 Added 1,490,743 +333,161 (28.8%) < 0.01% $13,491,224 2024-02-13
Q3 2023 Added 1,157,582 +58,987 (5.4%) < 0.01% $7,385,373 2023-11-15
Q2 2023 Reduced 1,098,595 -153,867 (-12.3%) < 0.01% $12,183,418 2023-08-14
Q1 2023 Added 1,252,462 +227,610 (22.2%) < 0.01% $19,225,292 2023-05-15
Q4 2022 Added 1,024,852 +944,272 (1171.8%) < 0.01% $22,741,465 2023-02-14
Q3 2022 Reduced 80,580 -53,465 (-39.9%) < 0.01% $1,315,000 2022-11-14
Q2 2022 Added 134,045 +24,673 (22.6%) < 0.01% $1,949,000 2022-08-15
Q1 2022 Added 109,372 +34,555 (46.2%) < 0.01% $2,021,000 2022-05-13
Q4 2021 Reduced 74,817 -48,020 (-39.1%) < 0.01% $1,778,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

114 managers reported AVIDITY BIOSCIENCES INC for Q2 2022.

Managers reporting AVIDITY BIOSCIENCES INC in Q2 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
PRICE T ROWE ASSOCIATES INC MD Reduced 7,883,125 -102,410 0.01% $114,542,000 9 qtrs
RTW INVESTMENTS LP Unchanged 4,795,000 0 1.8% $69,671,000 9 qtrs
BlackRock Inc Added 3,931,662 +665,653 < 0.01% $57,125,000 9 qtrs
FMR LLC Reduced 3,809,123 -1,792 < 0.01% $55,346,558 9 qtrs
EcoR1 Capital LLC Unchanged 2,759,505 0 1.38% $40,096,000 9 qtrs
FEDERATED HERMES INC Unchanged 2,474,500 0 0.1% $35,954,000 9 qtrs
VANGUARD GROUP INC Added 2,422,122 +123,759 < 0.01% $35,194,000 9 qtrs
COWEN AND COMPANY LLC New 2,264,150 +2,264,150 3.18% $32,898,000 1 qtr
RA CAPITAL MANAGEMENT L P Unchanged 2,167,391 0 0.84% $31,492,000 4 qtrs
Avidity Partners Management LP Added 2,080,200 +35,200 0.69% $30,225,000 4 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2022
Filed
August 15, 2022
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
132,993
Shared
472
None
580

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.